REUTERS: Moderna Inc and Merck & Co on Tuesday told a US Congressional panel that they expect to profit from their coronavirus vaccines once approved, amid concerns the vaccines may not be accessible to all.
Gerberding and a representative from Moderna did not comment on the price they have in mind for their vaccines at the hearing, which focused on efforts to develop a safe, effective and widely accessible vaccine against COVID-19, which has claimed 600,000 lives globally. "We didn't access federal funding solely for the reason that we wanted to move the vaccine faster to the clinic," Young said.